Quarterly report pursuant to Section 13 or 15(d)

Condensed Statement Of Operations

v2.4.0.8
Condensed Statement Of Operations (USD $)
3 Months Ended 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2014
Jun. 30, 2013
Revenues:        
Research            
Expenses:        
General and administrative 1,702,489 857,946 3,115,945 2,068,698
Research and development 1,701,407 925,130 2,972,981 1,477,596
Patent fees 95,410 121,216 167,430 257,707
Depreciation and amortization 9,630 9,235 18,674 18,551
Total Expenses 3,508,936 1,913,527 6,275,030 3,822,552
Loss from Operations (3,508,936) (1,913,527) (6,275,030) (3,822,552)
Other Income (Expense)        
Interest income 38,035 11,433 70,326 21,451
Unrealized gain/(loss) on fair value of warrants 3,665,365 (1,206,656) (7,995,159) (837,754)
Financing expense     (206,172)  
Total Other Income (Expense) 3,703,400 (1,195,223) (8,131,005) (816,303)
Income (Loss) Before Provision for Income Taxes 194,464 (3,108,750) (14,406,035) (4,638,855)
Provision for income taxes            
Net Income (Loss) $ 194,464 $ (3,108,750) $ (14,406,035) $ (4,638,855)
Net income (loss) per share, basic and diluted $ 0.00 $ (0.03) $ (0.08) $ (0.04)
Weighted average number of shares outstanding, basic and diluted 177,729,738 119,547,716 173,942,196 119,488,693